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One of the most important applications of nanotechnology is the drug delivery system 
that aims to develop nanomedicines able to deliver the therapeutic compounds into the 
diseased organ. The formulation and evaluation of drug delivery systems for example 
liposomes and lipid nanoparticis is less expensive than developing new drugs and can fulfill 
the objective of increasing the therapeutic activity and decreasing the toxic side effects. 
This thesis has three chapters. In the first chapter, we introduced a brief background 
on nanotechnology and drug delivery, liposomes as drug delivery systems, nonomedicine 
against malaria and nonomedicine against cancer. In this chapter, we also discussed the 
importance of using drug delivery nanomedicines to fight infectious diseases like malaria and 
serious diseases as cancer.  
In the second chapter, a liposomal nano drug delivery formulation was prepared to 
face resistant malaria parasites. The trans platinum-chloroquine diphosphate dichloride 
(PtCQ) is a new type of antimalarial drug used to fight parasites resistant to traditional drugs. 
PtCQ is synthesized by mixing platinum and chloroquine diphosphate (CQ). This study 
examines two efficient methods for forming a nanodrug, PtCQ-loaded liposomes, for use as a 
potential antimalarial drug-delivery system: the thin drug-lipid film method to incorporate the 
drug into a liposomal membrane, and a remote-loading method to load the drug into the 
interior of a cationic liposome. The membranes accordingly comprised PEGylated (contain 
polyethylene glycol (PEG) polymer) neutral or cationic liposomes. PtCQ was efficiently 
loaded into PEGylated neutral and cationic liposomes using the thin drug-lipid film method 
(encapsulation efficiency, EE: 76.1 ± 6.7% for neutral liposomes, 1:14 drug-to-lipid weight 
ratio; 70.4 ± 9.8% for cationic liposomes, 1:14 drug-to-lipid weight ratio. More PtCQ was 
loaded into PEGylated neutral liposomes using the remote-loading method than by the thin 
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drug-lipid film method and the EE was maximum (96.1 ± 4.5 % for neutral liposomes, 1:7 
(w/w)). PtCQ was encapsulated in PEGylated cationic liposomes comprising various amounts 
of cationic lipids (0-20 mol%; EE: 96.9-92.3%) using the remote-loading method. PEGylated 
neutral liposomes and cationic liposomes exhibited minimum leakage of PtCQ after two 
months’ storage at 4˚C, and further exhibited little release under in vitro culture conditions at 
37˚C for 72 hours. These results provide a useful framework for the design of future 
liposome-based in vivo drug delivery systems targeting the malaria parasite. 
In the third chapter, a marinosomal nano drug delivery formulation was prepared to 
face lung cancer, which considered as the major cause of cancer-related death worldwide. 
Curcumin attracted attention due to its promising anti-cancer properties, however its poor 
aqueous solubility and bioavailability have to be overcome. In the current study curcumin is 
encapsulated in krill lipids-based liposomes (marinosomes) to develop a potential anticancer 
therapy from low-cost and readily available nutraceuticals. Reflux followed by thin drug-lipid 
film method is used successfully to incorporate the drug into the liposomal membrane at high 
encapsulation efficiency (EE). The curcumin-loaded marinosomes (CURMs) showed a 
powerful antioxidant activity (EC50: 4.1 ± 0.3 μg/mL). Additionally, CURMs exhibited high 
physicochemical and oxidative stability after eight weeks’ storage at 4˚C. Furthermore, 
CURMs exhibited sustained release of about 30 % of their curcumin content under in vitro 
culture conditions at 37˚C after 72 hrs. Consequently, CURMs showed its maximum 
cytotoxic effect (IC50; 11.7 ± 0.24 μg/ml) after incubation for 72 hrs against adenocarcinomic 
human alveolar basal (A549) cells. Additionally, CURMs inhibited the proliferation of human 
umbilical vein endothelial cells (HUVECs) in a dose-dependent manner with IC50 of 2.5 ± 2.1 
μg/ml. The current study presents the CURM as a favorable in vitro drug delivery system to 
target cancer disease. 
 




 Introduction and objectives 
  
1.1. Background 
1.1.1 Nanotechnology and drug delivery 
From being a relatively small field to a worldwide scientific and industrial field, 
nanotechnology has been sprung in the last decades. One of the aims of nanotechnology 
is the development of functional materials, devices and systems in the nanometer scale. 
The biological functions depend mainly on the nanoscale dimensions of the cellular 
components where these functions take place (Li et al., 2017). Consequently, 
nanomaterials are similar in size to these biologic molecules and small enough to interact 
with and deliver to them. One of the most important applications of nanotechnology is 
the drug delivery system that aims to develop nanomedicines able to deliver the 
therapeutic compounds into the diseased organ (Shi et al., 2010). Therefore, drug delivery 
system is able to improve the solubility of hydrophobic drugs, reduce the potential 
immunogenicity, release the drugs in a sustained release phenomenom, increase the 
therapeutic activity and decrease the toxic side effects. Different biodegradable materials, 
including natural or synthetic polymers, lipids, or metals were used in preparation of 
nanoparticles and used as drug delivery systems (Suri et al., 2007). These drug delivery 
systems were generally < 100 nm and taken up by cells more efficiently while the drug 
can either be integrated in the matrix of the particle or attached to the particle surface. To 
 CHAPTER 1: Introduction and objectives 
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control the drug entering into the biological environment, nano drug delivery targeting 
systems with different compositions and biological properties have been plentifully 
investigated for drug and gene delivery applications (Pison et al., 2006; Schatzlein et al., 
2006; Brannon-Peppase et al., 2004; Yokoyama et al., 2005; Stylios et al., 2005). 
 
1.1.2 Liposomes as drug delivery systems  
Colloidal drug delivery systems such as liposomes, micelles or nanoparticles have 
been plentifully investigated for using in cancer therapy, shown in Fig. 1. The first 
description of swollen phospholipid systems has been reported in 1965 and followed by 
establishing the basis for model membrane systems (Bangham et al., 1965; 
Papahadjopoulos et al., 1967; Bangham et al., 1967). Bangosomes, which are enclosed 
phospholipid bilayer structures consisting of single bilayer, were the initial term of 
liposomes that described later (Deamer et al., 2010; Batzri et al., 1973). liposomes 
cabability to entrap drugs and to be used as drug delivery systems is a concept that is 
established by Gregory Gregoriadis (Gregoriadis et al., 1971; Gregoriadis et al., 1973). 
Later, the cabability of liposomes to change the in vivo distribution of entrapped drugs 
has been investigated (Kimelberg et al., 1976; Poste et al., 1976). Extrusion of 
multilamellar vesicles through polycarbonate membranes to produce large unilamellar 
vesicles (LUV) with defined size distribution was a particularly important advance 
(Olson et al., 1979). Sonication or homogenization was later used to produce “limit size” 
LUV with diameters less than 50 nm (Huang et al., 1969).  However, a scalable 
 CHAPTER 1: Introduction and objectives 
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production of LUV in the 20–50 nm size range was produced using microfluidic-mixing 




Fig. 1 Schematic representation of some colloidal drug delivery systems  
 
1.1.3 Nonomedicine against malaria 
Malaria is a life-threatening infectious disease that remains a major cause of death, 
caused by a parasitic protozoan, Plasmodium falciparum, and is transmitted by infected 
Anopheles mosquitoes. People living in the poorest countries are the most vulnerable, 
with approximately 80 % of deaths in Africa (World Malaria Report, 2015). The life 
cycle of Plasmodium parasites involves the injection of malaria parasite into the 
bloodstream (Greenwood et al., 2008; Miller et al., 2013). The parasite grows and divides 
in the erythrocytes by absorbing the nutrients from the blood. 
Most current antimalarial drugs distribute widely into body tissues and 
metabolized easily in the liver after systemic or oral administration because they are 
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amphiphilic (Greenwood et al., 2008). Consequently, a high dose that may cause toxic 
side effects is needed to provide a therapeutic effect. Lowering the dose to avoid toxicity 
lead to the development of resistance. Therefore, there is therefore an urgent need to 
develop new strategies to treat malaria and overcome the resistance of the parasite to 
current antimalarial drugs. These new strategies are including the formulation of novel 
delivery systems. The formulation and evaluation of drug delivery systems is less 
expensive than developing new drugs and can fulfill the objective of increasing drug 
bioavailability and thus increasing the therapeutic activity, decreasing side effects due to 
reduced dosing and increased selectivity of the drugs. Consequently, lipid nanoparticles 
such as liposomal formulations that encapsulate antimalarial drugs have been developed 
over the past years in order to test their utility in the treatment of malaria (Urbán et al., 
2011; Moles et al., 2015; Peeters et al., 1989; Santos-Magalhães et al., 2010). 
 
1.1.4 Nonomedicine against lung cancer 
Cancer is a major cause of morbidity and mortality, which affecting populations in all 
countries with approximately 14 million new cases and 8 million cancer-related deaths in 
2012 as estimated by the international Agency for Research on Cancer (GLOBOCAN, 
2012). Generally, the high-resource countries (North America, western Europe, Japan, 
Korea, Australia, and New Zealand) were found to have the highest incidence of cancer. 
The lowest incidence rates are seen in Africa and West and South Asia. Similar world 
maps of the estimated global age-standardized mortality rates. In contrast, the less 
economically developed countries show more cancer deaths for a given number of 
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incident cases, and cancer mortality rates are not very different from those in more 
developed countries. This could be due to clinical care, improved cancer survival and the 
good prognosis of cancers associated with a lifestyle of developed countries 
(Soerjomataram et al., 2015). 
 
Surgery, radiation, and chemotherapy are considered to be the conventional 
cancer therapies for cancer. Surgery has the incidence of operative mortality or 
postoperative complications. Radiation and chemotherapy may result in a lot of negative 
side effects including renal, neurologic, aplasia, pneumonitis and pericarditis toxic effects. 
Additionally, the hydrophobicity of most of chemotherapeutic drugs, which leads to poor 
aquous solubility and low bioavailability, with the lack of selectivity for the cancer cells 
result in the development of multidrug resistance (Chidambaram et al., 2011). In order to 
maximize tumor control and minimize chemotherapy side effects, potential alternatives 
and non-toxic therapies for lung cancer have to be continuing investigated. 
Nanotherapeutics is a rapidly progressing field of cancer research and able to solve the 
above-mentioned side effects of conventional chemotherapy. Nanotechnology provides 
nanoparticles that are able to increase the drug solubility, bioavailability and deliver 
chemotherapies directly and specifically to cancer cells in order to decrease or eliminate 








The objective of this study is facing infectious diseases as malaria and serious 
diseases like cancer using nanotechnology. One of the most important applications of 
nanotechnology is the drug delivery system that aims to develop nanomedicines able to 
deliver the therapeutic compounds into the diseased organ. The formulation and 
evaluation of drug delivery systems for example liposomes and lipid nanoparticis is less 
expensive than developing new drugs and can fulfill the objective of: 
 
1- Improving the solubility of hydrophobic drugs 
2- Increasing the encapsulation efficiency  
3- Releasing the drugs in a sustained release phenomenon. 
4- Increasing the therapeutic activity 
5- Decreasing the toxic side effects 
6- Decreasing the cost 
In the current study, two nano drug delivery systems were developed and 
characterized. One is for malaria, which is among the biggest killer diseases in the 
developing world. Platinum Chloroquine Diphosphate Dichloride complex (PtCQ) 
showed therapeutic effects againt chloroquine resistant malaria parasites. However and 
for the first time to encapsulate PtCQ into cationic liposomes with high encapsulation 
efficiency and high stability using remote loading method employing ammonium sulfate 
gradient. These PtCQ cationic liposomes hold promise for the future treatment of malaria 
and serious diseases. The other nano drug delivery system is for cancer, which is among 
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the leading killers in the developed countries. To the best of our knowledge, it is the first 
time to use krill lipid based liposomes to encapsulate a highly hydrophobic compound to 
prepare a low cost controlled drug delivery medicine to target cancer and other 
inflammatory diseases. These curcumin-loaded marinosomes exhibit high encapsulation 
efficiency, high antioxidant activity, and high physicochemical and oxidative stability. 
These curcumin-loaded marinosomes exhibited an effective cytotoxic effect on lung 
cancer (A549) and HUVEC cells. Hope these two drug delivery systems to be two 
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Effective loading of platinum–chloroquine into PEGylated 
neutral and cationic liposomes as a drug delivery system for 
resistant malaria parasites 
 
2.1. Introduction 
Malaria is a life-threatening infectious disease that remains a major cause of death, 
especially in tropical regions. The WHO estimated that 214 million new cases of malaria 
resulted in 438000 deaths in 2015 (WHO, 2015). The mortality rate of malaria is higher 
than that caused by AIDS. Malaria is caused by a parasitic protozoan, Plasmodium 
falciparum, and is transmitted by infected Anopheles mosquitoes. The life cycle of 
Plasmodium parasites involves being bitten by an infected mosquito, during which the 
malaria parasite is injected into the bloodstream (Greenwood et al., 2008; Miller et al., 
2013). The parasite migrates into hepatocytes and establishes itself in the liver. After a 
few weeks of dormancy, the activated parasite enters the blood and then infiltrates 
erythrocytes (red blood cells; RBCs). The parasite grows and divides in the erythrocytes 
by absorbing the nutrients from the blood via transporters, and these transporters are 
currently a topic of investigation by medical researchers.  
 
The amphiphilicity of most current antimalarial drugs lead them to distribute 
widely into body tissues after systemic or oral administration, and can be easily 
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metabolized in the liver (Greenwood et al., 2008), and thus a high dose that may cause 
toxic side effects is needed to provide an antimalarial effect. The need to lower the dose 
to avoid toxicity is likely a main factor contributing to the development of resistance; this 
low dose also means that an ineffective dose is delivered to Plasmodium-infected RBCs. 
There is therefore an urgent need to develop new strategies to treat malaria and overcome 
the resistance of the parasite to current antimalarial drugs, especially in regions where 
Plasmodium falciparum is endemic. 
 
Lipid-based drug nano-carriers have various advantages for drug delivery (Baruah 
et al., 2017). For example, liposomal formulations can increase drug bioavailability and 
thus increase therapeutic activity, decreasing side effects due to reduced dosing. 
Plasmodium-infected RBCs are the main chemotherapeutic target because several life 
stages of the parasite occur in the blood and give rise to the symptoms and pathologies of 
malaria. Consequently, several liposomal formulations encapsulating antimalarial drugs 
have been developed over the past several years in order to test their utility in malaria 
chemotherapy (Peeters et al., 1989; Santos-Magalhães et al., 2010). Additionally, 
immunoliposomes have been widely investigated and showed significant therapeutic 
effects (Urbán et al., 2011; Moles et al., 2015). However, one of the most drawbacks of 
immunoliposomes is that the antigens from different subspecies of malarial parasites are 
different. Therefore novel and universal drug delivery systems, which have effective 
targeting ability against various kinds of malaria parasites have been pursuing. 
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The ability of cationic liposomes to be adsorbed onto the cell surface and fuse 
with the negatively charged cellular membranes and thus deliver their cargo has been 
previously reported and shown in Fig. 2 (Li et al., 1997; Stebelska et al., 2006; Obata et 
al., 2010; Campbell et al., 2009; Zhao et al., 2011; Abu Lila et al., 2009). Anionic lipids 
such as phosphatidylserine (PS) are typically located within the inner monolayer of 
erythrocytes. The infection of erythrocytes with the malaria parasite leads to erythrocyte 
apoptosis, and this suicidal erythrocyte death is called eryptosis. The main characteristic 
stage of eryptosis is lipid scrambling and exposure of negatively charged PS on the outer 
surface of erythrocytes (Tagami et al., 2015; Föller et al., 2009), which increase the 
ability of erythrocytes to fuse with cationic liposomes (Stebelska et al., 2006). However, 
the use of cationic liposomes in vivo is limited due to their short circulation time, which 
leads to their recognition by the immune system including macrophages (Levchenko et 
al., 2002; Johnstone et al., 2001; Campbell et al., 2002). It is well known that 
polyethylene glycol (PEG) prevents the interaction with the biological in vivo 
environment and extend the circulation time of liposomes in blood. Cationic liposomes 
are therefore promising candidates for drug delivery targeting malaria-infected RBCs, but 
currently there is little information regarding the use of cationic liposomes. Additionally, 





CHAPTER 2: Effective loading of platinum–chloroquine into PEGylated neutral and cationic 








Fig. 2 Targeting of malaria-infected erythrocytes by cationic liposomes  
Cationic liposomes have the ability to fuse with the negatively charged 
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Hemoglobin catabolism is an essential process that provides the parasite with 
amino acids it needs to grow resulting in the formation of heme. For Energy production 
purpose, the parasite converts heme into hematin. As hematin is toxic, the parasite 
converts it into hemozoin, which is chemically identical to β-hematin. The mechanism of 
action of chloroquine (CQ) is based on the inhibition of detoxification of hematin 
products by the parasite through interaction with hematin and preventing the formation of 
hemozoin causing the parasite to be poisoned by its own metabolic products. Although 
promising were the CQ antimalrial effects, the emergence and spread of CQ-resistant 
parasites is a growing global health problem (Navarro et al., 2011; Urbán et al., 2011). 
PtCQ is a trans platinum-chloroquine complex that shows therapeutic effects against the 
chloroquine-resistant malaria parasite. The high lipophilicity of PtCQ and the structural 
modification of CQ imposed by the presence of Plattinum lead to enhanced activity and 
ability to lower CQ resistance. Consequently, the main mechanism of anti-malarial action 
of PtCQ was the interaction of this metal compound with the specific target 
ferriprotoporphyrin IX (Fe (III) PPIX) and inhibition of β-haematinin in order to increase 
anti-malarial activity and fight the parasite resistance (Navarro et al., 2011). 
 
The present study focuses on generating PtCQ-loaded PEGylated cationic 
liposomes exhibiting high drug encapsulation and high drug retention. Foremost, many 
fundamental properties of PtCQ, such as drug solubility, remain poorly investigated, 
although it was reported that PtCQ dissolves in dimethylsulphoxide (DMSO). We 
therefore investigated methods for efficiently loading PtCQ into liposomes and first 
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characterized the handling properties of PtCQ. Next; PtCQ was loaded with high 
encapsulation efficiency into cationic liposomes for the first time using the 
remote-loading method employing an ammonium sulfate gradient as shown in Fig. 3. The 
liposome formulations showed good drug retention, minimum leakage of PtCQ after two 
months’ storage at 4˚C, and further exhibited little release under in vitro culture 












Fig. 3 The efficient drug encapsulation into PEGylated cationic 
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2.2. Materials and Methods 
2.2.1 Reagents 
Chloroquine diphosphate (CQDP), potassium tetrachloroplatinate (K2[PtCl4]), 
hydrogenated soy phosphatidylcholine (HSPC), 
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and cholesterol (CHOL) were 
purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). 
1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene 
glycol)-2000] (DSPE-PEG2000) was generously donated by NOF Corporation (Tokyo, 
Japan).  
2.2.2 Synthesis of the trans-Pt(CQDP)2(Cl)2 complex (Navarro et al., 2011)  
The trans-Pt(CQDP)2(Cl)2 complex was synthesized as shown in Fig. 4. A 
solution of K2[PtCl4] (100 mg, 0.24 mmol) in water (30 ml) was stirred until it 
completely dissolved and then CQDP (250 mg, 0.48 mmol) was added. Stirring was 
continued for 18 hours at room temperature and a pink precipitate was obtained. This 
precipitate was collected by filtration, washed with water, and dried under vacuum. 
Yield 87.8% (calculated as in Fig. 5); elemental analysis (%) Calc. for 
C36H64N6Cl4O16P4Pt (1297.65 g.mol−1): C 33.3; N 6.5; H 4.9. Found: C 31.7; N 6.7; H 
4.4. IR υ (N-H) 3305 cm−1; υ (C=C) 1616 cm−1; υ (C=N) 1581 cm−1; υ (Pt-cl) 341 cm−1; υ 
(Pt-N) 420 cm−1. UV-vis 238 and 344 nm. 1H-NMR (DMSO-d6; δ ppm): 9.05 (1H; d; J, 
6.09 Hz; NH); 8.82 (1H; d; J, 9.13 Hz; H5); 8.58 (1H; d; J, 7.01 Hz; H2); 8.02 (1H; d; J, 
1.83 Hz; H8); 7.8 (1H; dd; J1, 1.83 and J2, 7.01 Hz; H6); 7.02 (1H; d; J, 7.01 Hz; H3); 
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4.17 (1H; m; H1 )́; 3.15 (6H, m, H4 ́ and H5 ́); 1.79 (4H; m; H2 ́ and H3 )́; 1.3 (3H; d; J, 







Fig. 4 Synthesis of platinum chloroquine diphosphate dichloride 
( PtCQ ) 
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2.2.3 Preparation of PtCQ-loaded liposomes using the thin drug-lipid film 
method 
Liposomes were prepared by the thin drug-lipid film hydration method, followed 
by membrane extrusion as shown in Fig. 6 and described previously, with minor 
modifications (Isacchi1 et al., 2011). Briefly, neutral PtCQ-loaded liposomes were 
prepared by dissolving each lipid powder (HSPC, CHOL and DSPE-PEG2000) with 
isopropanol and mixed at the molar ratio 55:45:5 (HSPC: CHOL: DSPE-PEG2000). PtCQ 
(1 mg) was dissolved in dichloromethane (DCM) and a trace of DMSO (The details in 
Fig. 7 and Fig. 8) and then added to the lipid mixture. The drug-lipid mixture was 
evaporated to give a thin drug-lipid film that was placed under high vacuum for at least 
overnight to remove residual solvent. The dried drug-lipid film was hydrated in HBS (20 
mM HEPES, 150 mM NaCl, pH 7.5) to form multilamellar vesicles (MLVs), sonicated 
for 10 min, and then extruded (Mini-extruder, Avanti Polar Lipids, Alabaster, AL, USA) 
10 times through Whatman Nuclepore Track-Etched polycarbonate membranes (GE 
Healthcare Life Sciences; Chicago, IL, USA) with 200 nm pores and then with 100 nm 
pores at 70˚C to transform the MLVs into unilamellar vesicles. The formulation was 
cooled on ice for 15 min and unencapsulated PtCQ was removed by ultracentrifugation 
(2.1104 g, 4˚C, 30 min) as previously reported (Laouini et al., 2012). Cationic 
PtCQ-loaded liposomes were prepared by dissolving the lipids (HSPC: DOTAP: CHOL: 
DSPE-PEG2000) in isopropanol, then mixing in the molar ratio 50:5:45:5, and 35:20:45:5. 
PtCQ (1 mg) was added to the lipid mixture at different weight ratios (1:7, 1:14) and then 
the vesicles were prepared as described above. The mean size and polydispersity index 
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(PDI) were determined using a dynamic light scattering instrument (ZetaSizer Nano-ZS; 
Malvern Instrument Ltd., Malvern, U.K). Zeta potentials were measured using Zetasizer 
Nano ZS90 (Malvern). The zeta potentials were measured by dispersing the liposome 
solution in 5% dextrose. The encapsulation efficiency (EE) was calculated as described in 





Fig. 6 Preparation of PtCQ-liposomes by thin drug-lipid film 
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Fig. 8 Optimal ratio of DMSO and DCM 
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2.2.4 Preparation of PtCQ-loaded liposomes using the remote-loading 
method 
PtCQ-loaded liposomes were prepared as as shown in Fig. 9 and previously 
reported, with minor modifications (Haran et al., 1993; Tagami et al., 2015; Tagami et al., 
2014; Qiu et al., 2008). Briefly, neutral PtCQ-loaded liposomes were prepared by mixing 
the lipids (HSPC: CHOL: DSPE-PEG2000) at the molar ratio 55:45:5. Cationic 
PtCQ-loaded liposomes were prepared by mixing the lipids (HSPC: DOTAP: CHOL: 
DSPE-PEG2000) with different molar ratios of the cationic lipid DOTAP (0, 5, 10, 15 and 
20 mol%) and dissolving in organic solvent. The solvent from the lipid mixtures was 
evaporated to provide thin lipid films that were placed under high vacuum for at least 
overnight to remove residual solvent. The thin films were hydrated with 250 mM 
ammonium sulfate (pH 4.0), sonicated for 10 min, and size-controlled liposomes were 
prepared using the extruder as described above. Next, the external liposomal phase was 
replaced with HBS via dialysis (Slide-A-Lyzer 10 kDa MWCO, Pierce Biotechnology, 
Rockford, IL, USA) for 24 h against 1000 volumes of HBS. The concentration of CHOL 
was determined using a cholesterol E-Wako kit (Wako Pure Chemical) and a microplate 
reader (Wallac 4000 ARVO multi-label counter; PerkinElmer, Waltham, MA, USA) in 
order to estimate the concentrations of the various liposome preparations. Neutral 
PtCQ-loaded liposomes were prepared by mixing PtCQ solution in HBS (0.65 mg/ml) 
with the neutral liposomal solution at three drug-to-lipid ratios (1:2.5, 1:5 and 1:7 (w/w) 
and incubated at 60˚C for 60 min for drug loading. The cationic PtCQ-loaded liposomes 
were prepared by using a drug/lipid ratio of 1:7 (w/w). The mean size, PDI, and zeta 
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potential were measured using Zetasizer Nano ZS90 (Malvern) as described above and 
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2.2.5 Determination of the EE 
For PtCQ-loaded liposomes prepared using the thin drug-lipid film method, 
the sample was ultracentrifuged (2.1104 g, 4˚C, minimum 30 min) and the pellet 
was resuspended in HBS buffer. The concentration of the encapsulated drug was 
measured by absorbance at 343 nm using a UV-visible spectrophotometer (UV-1800, 
Shimadzu, Kyoto, Japan) after completely disrupting the liposomes using 2% Triton 
X-100. The absorbance was converted into drug concentration using a standard 
curve. The EE was calculated using the previously reported equation (Ramana et al., 
2010):  
EE = (Drug Encapsulated / Total Drug) × 100% 
For PtCQ-loaded liposomes prepared using the remote-loading method, the 
samples were cooled and applied onto a gel filtration column (CL-4B, Sigma Aldrich, 
Saint Louis, MO, USA) equilibrated with HBS to remove unencapsulated PtCQ. The 
liposome fraction of the eluate was collected, the concentration of lipid was 
determined again, and the concentration of the encapsulated drug was measured as 
described above.  
 
2.2.6. Measurement of drug release from PtCQ-loaded liposomes under 
storage conditions  
All PtCQ-liposomal formulations were stored at 4˚C. As a typical experiment, 
aliquots (100 μl) were withdrawn at specified time points (0, 1, 2, 4 and 8 weeks), 
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diluted to 1 ml with HBS buffer, and ultracentrifuged (2.1104 g, 4˚C, 30 min) using 
Amicon filters (MWCO, 10K; Millipore, Bedford, MA, USA) to separate the released 
PtCQ. The released PtCQ was measured by absorbance at 343 nm as described 
above. The percentage of PtCQ released from the liposomes was calculated using the 
previously reported formula (Aditya et al., 2012):  
Drug release (%) = (PtCQ released / Total PtCQ) × 100  
Where “PtCQ released” indicates the amount of released PtCQ collected at a 
specified time point t and “Total PtCQ” indicates the total amount of PtCQ entrapped 
in the liposomes. 
 
2.2.7 Measurement of drug release from liposomes under in vitro culture 
conditions (release test)  
As a typical experiment, 1 ml of liposomal solution was mixed with 1 ml of 
RPMI 1640 medium (Wako Pure Chemical) supplemented with 10% heat-inactivated 
fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and the samples were incubated at 
37˚C in a humidified incubator in an atmosphere of 5% CO2/95% air. Aliquots (100 µL) 
were withdrawn at specified time points (0, 1, 3, 6, 24, 48 and 72 hours), diluted to 1 ml 
with HBS buffer, and ultra-centrifuged to separate the released PtCQ (2.1104 g, 4˚C, 30 
min). The percentage of PtCQ released was determined as in section 2.6. The 
chloroquine absorbance at 343 nm was unaffected by the culture medium, and the 
standard curve was unaffected, as shown in Fig. 10.  
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2.2.8 Statistical Analysis  
All data shown here are represented in “mean value ± standard deviation (S.D.)”. An 
ordinary one-way ANOVA (followed by Tukey's or Dunnett's multiple comparison test), 
and a two-way ANOVA with (Bonferroni post-test or Dunnett's multiple comparison test) 
were used to assess statistical significance by using GraphPad Prism (GraphPad Software 




      Fig. 10 Standard curve using HEPES and FBS 
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2.3. Results and discussion 
2.3.1 Synthesis and characterization of the Pt(CQDP)2(Cl)2 complex 
The platinum-chloroquine diphosphate complex was synthesized and isolated in 
water at room temperature. A mixture of K2[PtCl4] and CQDP was prepared to displace 
two chloride ligands, leading to the new PtCQ complex that was isolated in good yield as 
a pink solid precipitate (Fig. 11). The complex was characterized by elemental analysis, 
and UV-visible, IR and proton-NMR spectroscopy (for analysis data details, see section 
2.2 and Fig. 12). The complex is slightly soluble in water and insoluble in organic 
solvents except DMSO. The elemental analysis of this complex is in agreement with the 
molecular formula proposed. The IR spectrum of the complex shows peaks clearly 
associated with the presence of coordinated CQDP. In the 1H NMR spectrum, the 1H 
chemical shift variation of each signal with respect to that of the free ligand reported 
previously (Navarro et al., 2011) was similar and used to deduce the mode of bonding of 
CQDP to the metal. The largest shift 
with respect to the free ligand (CQDP) 
was observed for NH and H1 ́ as they 
are the nearest protons to the N-atom 
bonded to the metal, indicating that 
CQDP is bound to platinum through the 
nitrogen of the secondary amine. 
 
 
Fig. 11 Chemical structure of platinum 
chloroquine diphosphate dichloride 
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2.3.2. PtCQ-loaded liposomes prepared using the thin drug-lipid film 
method  
The high lipophilicity of metal chloroquine complexes has been previously 
reported (Navarro et al., 2014) and the preparation of highly stable lipophilic cisplatin 
complex/liposomes with high encapsulation ratios has been achieved (Khokhar et al., 
1991). Consequently, in this study we succeeded in loading the PtCQ complex into 
neutral and cationic liposomes at reasonable drug-to-lipid ratios by incorporating the drug 
into the lipid phase using the thin drug-lipid film method. As shown in Table 1, the 
PtCQ-loaded liposomes had uniform sizes ranging from about 105 nm to 143 nm and a 
narrow size distribution (PDI < 0.097). Furthermore, the zeta potential of PEGylated 
liposomes was changed from low negative (-7.1 ± 0.5 mV) of the neutral liposomes (1:7) 
to low positive (10.6 ± 0.9 mV, Cat.20) of the cationic liposomes (1:7). The negative 
charge of the neutral liposomes is due to the presence of negatively charged phosphate 
group in DSPE-PEG2000 (Woodle et al., 1992). In addition, Fig. 13 reveals that the 
cationic lipid content clearly affects the drug loading in the thin drug-lipid film method. 
Based on the statistical study, the addition of 5 mol% of the cationic lipid DOTAP at low 
liposome concentration (7 mg) has a significant decrease (p = 0.0076) on the EE% of 
Cat.20 compared to Cat.5, however it has no significant effect (p > 0.05) on the EE% of 
Cat.5 and Cat.20 compared to neutral liposomes. On the other hand, at higher liposome 
concentration (14 mg), there is a significant decrease (p < 0.0001) on the EE% of Cat.20 
compared to Cat.5 and the neutral liposomes, however no significant effect (p > 0.05) 
was noticed in the EE% of Cat.5 compared to the neutral liposomes. The decrease in the 
CHAPTER 2: Effective loading of platinum–chloroquine into PEGylated neutral and cationic 





EE% with the increase of the cationic lipid content could be due to the electrostatic 
repulsion between the cationic drug and the cationic lipid such as DOTAP.  
Table 1. PtCQ-liposomes loaded by thin drug–lipid film method 
 
Neutral and cationic formulations with drug–lipid (1:7, 1:14 w/w) have been 
prepared. The neutral lipids have been mixed with the molar ratio (55:45:5). The cationic 
lipids have been mixed with the molar ratio (5:50:45:5) and (35:20:45:5). Data represent 
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Fig. 13. The EE of liposomes prepared using the thin drug–lipid film method 
Three formulations were prepared, at drug to lipid ratios of 1:7, 1:14 (w/w). 
Data represent the mean ± S.D. (n = 3), (**** p < 0.0001, ** p = 0.0076). The 
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2.3.3 PtCQ-loaded liposomes prepared using the remote-loading method 
To our knowledge, this is the first report describing the encapsulation of the 
PtCQ complex into liposomes using an ammonium sulfate gradient and the results are 
promising. The rate of loading and the stability of the loaded drug in the intra-liposomal 
medium mainly depend on the properties of i) the loaded drug, ii) the intra-liposomal 
medium, and iii) the liposome bilayer, as discussed below.  
 
(i) Properties of the loaded drug: 
Chemical compounds can be categorized as hydrophilic compounds, amphiphilic 
compounds, and hydrophobic compounds. Hydrophilic compounds do not interact with 
the liposome bilayer and can be encapsulated in the aqueous phase of the liposome 
interior. Hydrophobic compounds integrate into the liposome bilayer. Amphiphilic 
compounds may be amenable to high loading due to their possible high affinity for the 
liposomal membrane or may be remotely loaded into the intra-liposomal aqueous phase 
by using a pH gradient. CQ is a diprotic amphiphilic weak base with two proton-binding 
groups: the side chain terminal amine (pKa1 = 10.2) and the quinoline nitrogen atom 
(pKa2 = 8.4). Accordingly, unprotonated CQ can be driven by a pH gradient across a 
parasite’s food vacuole membrane and thus accumulate in the acidic food vacuole.  
CQ can be actively encapsulated by applying a pH gradient (Qiu et al., 2008; 
Madden et al., 1990), during which it is protonated to the diproton form following 
exposure to the intra-liposomal acidic medium, then captured inside the liposomes due to 
the low permeability of the liposomal bilayer membrane to the protonated drug (Qiu et al., 
2008). In the present study we used the ammonium sulfate gradient to load PtCQ into 
CHAPTER 2: Effective loading of platinum–chloroquine into PEGylated neutral and cationic 





liposomes composed mainly of neutral or cationic saturated phospholipids with an EE of 











Fig. 14. Effect of increasing the liposomal content on the EE of PtCQ loaded 
inside neutral liposomes prepared using the remote loading method 
Three formulations were prepared, at drug to lipid ratios of 1:2.5, 1:5 and 1:7 
(w/w). Data represent the mean ± S.D. (n = 3). Statistical data infers that each group 
is significantly different (****p < 0.0001, ***p = 0.0008). The information about 
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Fig. 15. Effect of increasing the cationic lipid content (DOTAP) on the EE of PtCQ 
loaded inside cationic liposomes prepared using the remote loading method 
Five formulations were prepared (0, 5, 10, 15, 20 mol% as cationic lipid). The 
drug-to-lipid ratio is 1:7 (w/w). Data represent the mean ± S.D. (n = 4). The information 
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(ii) Intra-liposomal medium properties: 
Various chemical gradients have been used to create a trans-membrane potential 
as a driving force to facilitate the loading of a drug through an active loading mechanism. 
For example, ammonium sulfate induces a potential gradient for weak bases and acids 
and this gradient remains stable for over six months for liposomal formulations stored 
below the transition temperature of the phospholipids (Haran et al., 1993). Furthermore, 
lipophilic amino-containing drugs can be partitioned into the lipid bilayer, resulting in a 
drug gradient through the lipid bilayer that aids the influx of the drug from the outside to 
the inside (Harrigan et al., 1993). 
In the present study, we loaded the PtCQ complex into neutral liposomes using a 
pH gradient and the trans-membrane potential generated by an ammonium sulfate 
gradient as driving forces. Following hydration of the PtCQ-loaded liposomes using an 
ammonium sulfate solution, an equal concentration of ammonium sulfate is found outside 
and inside the liposomes. Removal of the outside ammonium sulfate solution by dialysis 
leads to an ammonium sulfate gradient in which the concentration of ammonium sulfate 
inside the liposomes is greater than that outside and the gradient is due to the large 
difference in the permeability coefficient through lipid bilayer as mentioned before 
(Haran et al., 1993). The higher concentration of ammonium inside the liposome causes 
the efflux of neutral ammonium, leaving the protons inside the liposome. This 
ammonium gradient results in the influx of the PtCQ into the acidic intra-liposomal 
medium and thus its encapsulation. The drug may be tetra-protonated due to the presence 
of two chloroquine molecules in the complex. The outside-inside pH gradient was 7.5–4 
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to give a pH gradient equal to 3.5 units (∆pH = (external pH − internal pH) = 3.5) since 
this produces a much higher inside concentration of the weak base compared to the 
outside concentration. As shown in Fig. 14 and Table 2, PtCQ-loaded liposomes were 
prepared with different drug-to-lipid weight ratios and the maximum EE was obtained at 
a drug-to-lipid ratio of 1:7 (w/w). In a preliminary experiment, the loading of PtCQ was 
compared using ammonium sulfate or citrate buffer and the EE was found to be higher 
with ammonium sulfate, perhaps due to the high permeability coefficient of the NH3 
molecule, which causes fast diffusion of neutral ammonia to the external medium of the 
liposomes. Each diffusing NH3 molecule leaves one proton inside the liposome, thus 
acidifying the intra-liposomal medium and resulting in a pH gradient and influx of the 
drug (Haran et al., 1993). The pH gradient had a greater effect on CQ, which has two 
amino moieties, than on a weak base with one amino moiety (Qiu et al., 2008). 
 
(iii) Liposome bilayer properties 
It was previously demonstrated that drug-loaded liposomes prepared by the 
remote loading method and comprising saturated lipids can be maintained at 4˚C for at 
least six months without deterioration (Haran et al., 1993). Liposomes composed of 
saturated lipids can maintain a pH gradient due to the relatively high transition 
temperature of the bilayer. In the present work, we used the saturated lipid HSPC to 
construct the membrane of PtCQ-loaded liposomes generated using the remote loading 
method. The demonstrated stability of the PtCQ-loaded liposomes under storage and 
culture conditions verifies the ability of this saturated lipid bilayer to maintain a specified 
pH gradient and retain the drug in the interior phase of the liposome as long as the 
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temperature does not exceed the transition temperature of the lipid, thus preventing 
thermal mobility that could disrupt the membrane required for maintaining the pH 
gradient (Qiu et al., 2008). We studied the effect of temperature on drug loading at two 
temperatures below the transition temperature 60˚C, after incubation for one hour and 
obtained maximum loading at 60˚C as described below.  
 
             Table 2. PtCQ-liposomes loaded by ammonium sulfate gradient 
 
The neutral lipids have been mixed with the molar ratio (HSPC/CHOL/DSPE- 
PEG2000 = 55:45:5). Three different formulations with drug–lipid (1:2.5, 1:5, 1:7 w/w) 
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2.3.4 Cationic PtCQ-loaded liposomes produced using the 
remote-loading method 
Five types of cationic PtCQ-loaded liposomes with a drug-to-lipid ratio of 1:7 
(w/w) but differing in the ratios of the constituent lipids were prepared and characterized, 
and the results are shown in Table 3. The PtCQ-loaded cationic liposomes has uniform 
sizes about 130 nm and a narrow size distribution (PDI < 0.05). It was reported that the 
cationic liposomes demonstrate an enhanced cellular uptake compared to the neutral 
liposomes, it could be due to the electrostatic interaction between the positive charge and 
the cell (Zhao et al., 2011). Additionally, the increase of cationic lipids in liposomes 
could lead to a higher affinity for the anionic sites, however it could result in their 
aggregation in the bloodstream through electrostatic interactions with the anionic species 
in the blood and thus increase their uptake by the RES (reticuloendothelial system) (Zhao 
et al., 2011). Liposomes are typically modified with PEG (PEGylation) to form a water 
layer that could prevent protein adsorption onto the liposome surface and decrease the 
uptake of PEG-liposomes by macrophages and thus help in prolonging the lifetime of 
liposomes in the blood circulation (Kraft et al., 2014). The partial coating of cationic 
particles with PEG masks the values of zeta potential (electric potential across a double 
membrane surface), however it can’t prevent them from binding to the cells and the 
biodistribution completely. Moribe et al., reported that the inclusion of 0 to 10% PEG 
sharply decreases zeta potential of the liposome (Moribe et al., 1997). For this reason 
typically 5–10 mol% of PEG is enough to delay the recognition of liposomes by immune 
system cells. This concentration could retain a significant cationic charge and binding to 
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the cells. Consequently, All formulations prepared in this study were PEGylated with 5 
mol %. Additionally, it has been reported that the adhesion of the liposome membrane to 
the cell depends on the ratio of the liposome–cell charge, thus the probability of adhesion 
is maximized at a finite polymer layer thickness in case of the cationic liposomes are 
overcharged compared to the cell (Dan et al., 2002). Accordingly, in this study, several 
PtCQ-loaded liposomes with different molar ratio of the cationic lipid (DOTAP, 0, 5, 10, 
15 and 20 mol%) were prepared to provide stable cationic PtCQ-loaded liposomes that 
could selectively bind to erythrocytes. Table 3 reveals that the zeta potential of 
PEGylated cationic liposomes changes from low negative (-7.5 ± 1.3) for (Cat.0) to 
neutral (-0.4 ± 0.7, Cat.10), and to low positive (10.7 ± 3.0, Cat.20).  
 
The addition of negatively charged lipids to liposomes generated using the 
passive loading method can increases EE due to electrostatic interaction between the 
positively charged chloroquine and the negatively charged liposomes. However, 
characterization of the PtCQ-loaded liposomes prepared using the thin drug-lipid film 
method presented in section 3.2 confirmed that the EE of cationic liposomes decrease 
with increasing the cationic lipid content and this could be due to the electrostatic 
repulsion between the cationic drug and the cationic lipid. In contrast, Fig. 15 reveals that 
the different cationic PtCQ-loaded liposomes prepared by ammonium sulfate gradient 
(Cat.5, Cat.10, Cat.15, and Cat.20) have no significant effect (p > 0.6559) on EE% 
compared to Cat.0 (96.9 ± 5.0%). This result confirms that the most of PtCQ loaded by 
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ammonium sulfate gradient is not bilayer-associated, in good agreement with a previous 
report (Haran et al., 1993).  
 
 
  Table 3. PtCQ-liposomes loaded by ammonium sulfate gradient 
 
The cationic lipids have been mixed with different molar ratios. Five different 
formulations with HSPC–DOTAP (55:0, 50:5, 45:10, 40:15, 35:20) have been prepared. 
Data represent the mean ± S.D. (n = 3, 4). 
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2.3.5 Drug release from cationic PtCQ-loaded liposomes under storage 
conditions (storage test) 
The stability of cationic PtCQ-loaded liposomes (cat.0, cat.5, cat.10, cat.15, 
cat.20) loaded using the ammonium sulfate gradient (drug-to-lipid ratio 1:7 (w/w)) was 
studied during eight weeks’ storage at 4˚C. Fig. 16 reveals that there is no significant 
release (p > 0.05) of the drug at different cationic PtCQ-loaded liposomes after eight 
weeks’ storage at 4˚C, compared to Cat.0 (5.7 ± 4.9 %). This demonstrates the utility of 
the ammonium sulfate gradient method for incorporating amphiphilic drugs into stable 
liposomes containing a saturated lipid (HSPC). It was reported that the addition of PEG 
stabilizes liposomes due to repulsive barrier resulted from steric pressure forces and 
charged phosphate moieties (Woodle et al., 1992; Needham et al., 1992). Additionally, 
the presence of CHOL stabilizes liposomal formulations, as reported previously (Briuglia 
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Fig. 16. Release pattern of PtCQ from cationic liposomes, Prepared by 
Remote Loading Method, in HEPES Buffer during Storage at 4°C. PtCQ was loaded 
into the liposomes at a drug-to-lipid ratio of 1:7 (w/w). Data represent the mean ± 
S.D. (n = 3). Cat. 0, Cat. 5, Cat. 10, Cat. 15 and Cat. 20 are the five formulations of 
cationic PtCQ-loaded liposomes prepared using different molar ratio of the cationic lipid 
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2.3.6 Drug release from cationic PtCQ-loaded liposomes under culture 
conditions (release test) 
A drug release study was carried out using medium containing FBS to mimic in 
vivo conditions. Figure 17 reveals that the PtCQ liposomes loaded by thin drug-lipid film 
method (drug to lipid ratio 1:7 (w/w)) have initial burst release equal to 8.9 ± 0.5% of 
neutral liposomes and equal to 13.2 ± 2.1% of cationic liposomes (Cat.5) at 0 hour. The 
cause for initial burst release may be due to the adsorption of some drug molecules on the 
liposome surface during formation of the thin film. Furthermore, after 72 hours, there is a 
significant drug release (p = 0.0001) of Cat.5 compared to neutral liposomes’cumulative 
release equal to 17.8 ± 2.6%. The cationic liposomes showed a maximum release which 
is slightly higher than that of neutral liposomes and this could be due to electrostatic 
repulsion between the cationic drug and the cationic lipid. 
The five formulations of cationic PtCQ-loaded liposomes (cat.0, cat.5, cat.10, 
cat.15, cat.20) loaded using an ammonium sulfate gradient (drug to lipid ratio 1:7 (w/w) 
described above didn't show initial burst release and showed no significant release (p > 
0.05) of the drug after 72 hours compared to Cat.0 (4.0 ± 2.3%), as shown in Figure 18. 
This demonstrates that the ammonium sulfate gradient is a promising method for the 
encapsulation of amphiphilic drugs into liposomes containing a saturated lipid (HSPC). 
Furthermore, the amount of drug released was sustainably released indicating that 
liposomes loaded with amphipathic weak bases using an ammonium sulfate gradient can 
provide controlled release of the loaded molecule. Increasing the cationic lipid from 0% 
to 20% mole percent has no significant effect on the release of the drug; showing that the 
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surface charge has no effect on the release of amphipathic weak bases loaded using 
ammonium sulfate and pH gradients. The slow drug release observed in case of 
ammonium sulfate gradient loaded PtCQ-liposomes is necessary for long storage and to 
avoid drug leaking before reaching their target (Moles et al., 2015). Afterward the 
liposomes would be adsorbed on the cell surface followed by a depletion of the liposomal 
proton gradient due to the body temperature or liposomes-cell interaction episodes. This 
depletion leads to accumulation of the weak basic drugs inside the RBC due to the 
electrochemical gradient resulted from the phospholipid asymmetry in RBC membranes, 
which maintains negatively charged membranes.  
 
Fig. 17. Release pattern of PtCQ 
from neutral and cationic 
liposomes, Prepared by thin 
drug–lipid film method, under 
culture conditions. PtCQ-loaded 
liposomes were incubated in 
medium containing 10 % FBS at 
37°C. PtCQ was loaded into the liposomes at a drug-to-lipid ratio of 1:7 (w/w). Data 
represent the mean ± S.D. (n = 3). (**** p < 0.0001, *** p = 0.0007, ** p = 0.0024) 
compared to neutral liposomes. 
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Fig. 18. Release pattern of PtCQ from cationic liposomes, Prepared by 
PtCQ-loaded liposomes were incubated in medium containing 10 % FBS at 37°C. 
PtCQ was loaded into the liposomes at a drug-to-lipid ratio of 1:7 (w/w). Data 
represent the mean ± S.D. (n = 3). Cat. 0, Cat. 5, Cat. 10, Cat. 15 and Cat. 20 are the 
five formulations of cationic PtCQ-loaded liposomes prepared using different molar ratio 
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This chapter described the synthesis and characterization of the 
trans-platinum-chloroquine complex (PtCQ) and the application of two methods to 
generate PtCQ-loaded liposomes: the thin drug-lipid film and the remote loading methods. 
Liposomes of uniform diameter were prepared using the thin film hydration and extrusion 
technique and the PtCQ was encapsulated in the liposomes. The most efficient 
encapsulation was obtained at a drug-to-lipid ratio of 1:7 (w/w) using the ammonium 
sulfate gradient active loading method. This approach provided liposomal formulations 
capable of sustaining a proton gradient for the weak basic drug PtCQ and the 
encapsulation efficiency was approximately 100%. High intra-liposomal retention levels 
of 93% the drug inside different cationic liposomes for several hours under culture and 
storage conditions were maintained, suggesting that such liposomes hold promise for the 
future treatment of malaria by targeting Plasmodium falciparum. We will study the in 
vitro and in vivo effects of cationic PtCQ-loaded liposomes on this parasite and the 
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CHAPTER 3  
Curcumin marinosomes as promising nano-drug 




Lung cancer is the major cause of cancer-related deaths worldwide with the 
non-small cell lung cancer (NSCLC) accounts about 80 % of all lung cancer cases. 
Surgical removal is the standard treatment for early-stage NSCLC with the danger of 
postoperative complications (National Comprehensive Cancer Network Guideline 
2018). Platinum-based chemotherapy and radiation are the standard therapies for 
advanced NSCLC (Mehta et al., 2014). Radiation and chemotherapy may result in a 
lot of negative side effects, including renal and neurologic toxic effects, aplasia, 
pneumonitis and pericarditis. In order to augment tumor control and diminish 
chemotherapy side effects, potential alternatives and non-toxic therapies for lung 
cancer have to be continuing investigated.  
 
 Curcumin, which is a polyphenolic hydrophobic natural compound derived 
from the rhizomes of Curcuma longa, has been used to treat various disorders due to 
its safety and cost-effectiveness. Curcumin has been reported to target several 
molecules involved in the multistep carcinogenesis (Mehta et al., 2014). Meaning that 
curcumin can target tumor suppressor genes, cyclooxygenases and lipoxygenases to 
induce anti-carcinogenic and anti-inflammatory effects (Hong et al., 2004). Curcumin 
also suppresses the expression of tumor necrosis factor alpha that is an inflammatory 






cytokine to control the progress of most tumor cells. Additionally, curcumin 
modulates the expression of transcription factors to act as anti-proliferative, 
anti-inflammatory, anti-angiogenic and anti-metastatic agent (Balasubramanyam et al., 
2004; Bharti et al., 2003; Bierhaus et al., 1997; Pendurthi and Rao, 2000; Shishodia et 
al., 2003). Together these studies implicate that curcumin could be a promising 
chemopreventive agent for lung cancer treatment. Despite the promising effects of 
curcumin against cancer and numerous diseases, its light sensitivity, poor solubility in 
aqueous medium and poor bioavailability are issues make it less useful as a 
therapeutic agent and have to be overcome in order to avail the entire benefits of this 
plant-extracted compound (Anand et al., 2007). Nano-formulations of curcumin using 
liposomes (Li et al., 2005), polymeric nanoparticles (Bisht et al., 2007), lipid 
nanoparticles (Sou et al., 2008), nanoemulsions (Ahmed et al., 2012), and 
cyclodextrins (Desai, 2010) have been extensively investigating in order to enhance 
drug solubility, bioavailability, the therapeutic efficacy and cause controlled release 
of the drug. Although promising were these attempts, they showed some 
disadvantages like excipients’ high cost, innate cytotoxicity or limited drug loading 
and entrapment efficiency. Consequently, the encapsulation of curcumin into 
naturally occurring compound could help to develop a potential anticancer therapy 
from low-cost and readily available nutaceuticals.  
  
Marinosomes are marine lipid-based liposomes containing a high ratio of 
polyunsaturated fatty acids (PUFAs) (Moussaoui et al., 2002). Marine PUFAs are 
divided into two subgroups: omega-6 (n-6) and omega-3 (n-3) that are metabolized 
and stored in cell membrane phospholipids (Schmitz and Ecker, 2008). They 






influence membrane fluidity, regulate a wide range of functions in the body and 
correct development and functioning of the brain and nervous systems (Das, 2006). In 
marine lipids, extracted from marine organisms like krill, a large portion of n-3 
PUFAs are bound to phospholipids and includes a higher content of n-3 long chain 
PUFAs such as eicosapentaenoic acid (EPA; 20:5 n-3) and docosahexaenoic acid 
(DHA; 22:6 n-3) (Peng et al., 2003; Winther et al., 2011). Marine phospholipids have 
high bioavailability compared with triglyceride are efficiently taken up into body 
tissues (Wijendran et al., 2002). It is previously reported that a diet including high n-3 
long chain PUFA, such as the Japanese and Mediterranean diets, has lower 
occurrence of cancer (Gerber, 2012). N-3 PUFAs have been used in the prevention 
and treatment of cancer through various mechanisms (Vaughan et al., 2013). A likely 
mechanism of cancer prevention through the anti-inflammatory properties of n-3 
PUFAs has been reported (Alaarg et al., 2016). Other studies have reported different 
mechanisms of cancer prevention by n-3 PUFAs including apoptosis, inhibition of 
angiogenesis, inhibition of metastasis and others (Blanckaert et al., 2010; Iigo et al., 
1997; Yin et al., 2017). Actually, n-3 PUFAs are not only beneficial in cancer 
treatment but also in other diseases that share the same common physiopathological 
features like unbalanced oxidative stress, inflammation and abnormal cell 
proliferation (Calder, 2012; Ross et al., 2001). 
 
Despite the promising effects of n-3 PUFAs against cancer and other 
numerous diseases, it has been reported that their effects are typically observed after 
long-term oral consumption at a relatively high amount (Geusens et al., 1994; 
Schmidt et al., 1992). The use of nanomedicine to increase the levels of n-3 PUFAs in 






inflamed tissues has been studied (Alaarg et al., 2016). Additionally, effective and 
low-cost anticancer combination drugs were developed from curcumin with other 
naturally occurring nutraceuticals (Choudhury et al., 2013). To benefit wholly from 
the effects of both n-3 PUFAs and curcumin, together nanomedicine with drug 
combination strategy will be used to propose a novel liposomal formulation of 
curcumin-loaded PUFAs liposomes (curcumin marinosomes; CURMs, Fig. 19). Such 
liposomal formulation could improve the bioavailability of curcumin, causes 
controlled release and leads to increased stability, antioxidant and anticancer activity. 
In this study, the physicochemical characteristics of CURMs and their antioxidant 
activity are reported. Additionally, the growth-arresting effects of CURMs on A549 
























Fig. 19 Graphical abstract 
The encapsulation of curcumin into krill lipid-based liposomes, which are readily 
available neutraceuticals to prepare nano controlled anticancer therapy, 











3.2. Materials and Methods 
3.2.1 Materials 
Curcumin was purchased from Sigma Aldrich. 2,2-diphenyl-l-picrylhydrazyl 
(DPPH) was purchased from Wako Pure Chemical (Osaka, Japan). Ethanol, 
chloroform and methanol were purchased from Wako Pure Chemical. PBS tablets 
were purchased from Takara Bio Inc. (Shiga, Japan).  
The natural lipid mixture extracted from krill was supplied by Nippon Suisan 
company (Tokyo, Japan). The lipid extract analyzed by Japan Food Research 
Laboratories (Tokyo, Japan) contained the following weight percentages: saturated 
fatty acids (14.4 %), monounsaturated fatty acids (18.3 %), PUFAs (63.5 %), and 
inorganic metals, cholesterol, vitamin E, and dietary fibers (3.8 %). The fatty acids 
composition was determined using hydrogen flame ionization detection-gas 
chromatograph method. The polyunsaturated fatty acids were found to contain n-3 
PUFAs (51.4 %) and n-6 PUFAs (3.1 %). The n-3 PUFAs were found to contain the 
following fatty acids: eicosapentaenoic acid (29.2 %; EPA (n-3)), docosahexaenoic 
acid (12.7 %: DHA (n-3)), octadecatetraenoic acid (3.7 % (n-3)) and 
docosapentaenoic acid (2.9 % (n-3)). The monounsaturated fatty acids were found to 
contain the following fatty acids: palmitoleic acid (9.2 % (n-7)), oleic acid (8.1 % 
(n-9)) and others (1 %). The saturated fatty acids were found to contain the following 










3.2.2 Preparation of CURMs using the thin drug-lipid film hydration 
method  
CURMs were prepared by reflux followed by thin drug-lipid film hydration 
method, which mentioned in details in chapter 2 with some modification. Krill lipids 
were taken with different weights (10, 15, 20, and 30 mg) in a glass bottle and 
dissolved in chloroform/methanol mixture (2/1, v/v). Curcumin (1 mg) was added to 
the lipid solution and the mixture was refluxed (tightly close the glass bottle and stir 
at a temperature of 50˚C for 2 h, Fig. 20). The resultant clear solution was evaporated 
to provide thin lipid films that were placed under high vacuum for at least overnight 
to remove the residual solvent. The dried drug-lipid film was hydrated in HBS to form 
MLVs. For the CURMs prepared using extrusion method, the MLVs were extruded 
10 times through two Whatman Nucleopore Track-Etched polycarbonate membranes 
with 200 nm pores at 50˚C to decrease their sizes. For the CURMs prepared using 
sonication, the MLVs were sized using an ultra-sonic homogenizer (UH-50; SMT 
Company, Tokyo, Japan). The prepared formulations were cooled on ice for 15 min 
and unencapsulated curcumin was removed by centrifugation (1.5  103 g, 4˚C, 15 
min). The mean size and polydispersity index (PDI) were determined using a dynamic 
light scattering instrument. Zeta potentials were measured using ZetaSizer Nano ZS90. 















       Fig. 20 Curcumin-loaded marinosomes preparation method 
Curcumin was added to the lipid solution and the mixture was refluxed in water bath 
(W.B) and stir at a temperature of 50˚C for 2 h. After evaporation, hydration and 











3.2.3 Determination of DPPH stability in detergent buffer solution 
Method 
The DPPH stability in detergent buffer solution was determined as previously 
reported after modification (Nicklisch and Waite, 2014). DPPH ethanolic solution at a 
concentration of 2 mM was freshly prepared in a glass bottle wrapped in aluminum 
foil to prevent photochemical decomposition. 1 ml of the 2 mM DPPH stock solution 
was added to 19 ml HBS treated with 0.3 % Triton X-100, the final concentration 
became 0.1 mM DPPH. The HBS-Triton mixture solution was wrapped in aluminum 
foil, mixed gently and incubated at room temperature in dark condition. In a 
spectrophotometer cuvette and after each predetermined time, a certain volume of 
HBS-Triton mixture was withdrawn and the absorbance was measured at 517 nm 
using a UV-visible spectrophotometer. A comparative study to prospect the capability 
of this HBS-Triton mixture to maintain the DPPH stability has been performed. The 
same method at the same conditions was repeated to measure the stability of DPPH in 
HBS buffer and methanol. 
 
3.2.4 Determination of the antioxidant activity of CURMs in 
detergent buffer solution 
The free radical scavenging activities of vitamin C, CURMs prepared by 
extrusion (CURME), CURMs prepared by sonication (CURMS), free curcumin and 
free marinosomes (FMs) were determined using DPPH assay as previously reported 
after modification (Aadinath et al., 2016). CURME, CURMS, and free curcumin were 
prepared with different concentrations ranging from 1.56 g/ml to 25 g/ml, added to 
different test tubes and adjusted to 950 l using detergent buffer. Vitamin C as 






positive control was dissolved in HBS buffer with concentration 1 mg/ml as a stock, 
and then different concentrations ranging from 1.56 g/ml to 25 g/ml were prepared 
using the detergent buffer. This detergent buffer is HBS treated 0.3 % Triton X-100 as 
previously reported after modification (Nicklisch and Waite, 2014). FMs were 
prepared at different concentrations of lipids ranging from 23.4 g/ml to 375 g/ml, 
which encapsulate the herein above-mentioned curcumin concentrations. Later 50 l 
of 2 mM DPPH ethanolic solution was added to these tubes, the final concentration 
became 0.1 mM DPPH. The tubes were shaken and allowed to stand at room 
temperature for 40 min in dark condition. The control was prepared as mentioned 
above without the sample, and HBS-Triton mixture was used as a reference. A certain 
volume (230 l/well) is transferred to 96-well plate and the absorbance was measured 
at 517 nm by using microplate reader (Wallac 4000 ARVO multi-label counter; 
PerkinElmer, Waltham, MA, USA). The antioxidant activity was calculated using the 
following formula: 
Antioxidant activity % = (Abs control - Abs sample / Abs control) × 100 
Where, Abs control and Abs sample are the absorbance values of the control and 
sample respectively. The EC50 values, which are the concentrations of samples 
required to obtain 50 % antioxidant activity, were determined based on the 











3.2.5 Stability of CURMs under storage condition 
CURMs were stored at 4˚C. As a typical experiment, the samples were 
centrifuged (1.5×103 g, 4˚C, 15 min) and aliquots were withdrawn at specified time 
points (0, 1, 2, 3, 4 ~ 8 weeks) as reported previously (Chen et al., 2015). Variations 
in the particle size, PDI and curcumin retention were measured. Additionally, the 
oxidative stability was determined following the same procedure mentioned in 
section 3.2.4 The curcumin retention percentage was determined using 
spectrophotometer as described in chapter 2, and from the following equation as 
reported previously (Jin et al., 2016): 
Curcumin retention %= (CUR Retained / CUR Encapsulated) × 100 
Where CUR Retained is the amount of curcumin remained after the predetermined 
time and the CUR Encapsulated is the amount of curcumin that measured directly 
after preparation. 
 
3.2.6 Retention of CURMs under culture condition 
To test the retention of curcumin under in vitro culture conditions, a series of 
test tubes were prepared. In every test tube, 100 l of CURMs was mixed with 100 l 
of Dulbecco's Modified Eagle Medium (DMEM; Wako Pure Chemical) supplemented 
with 10 % heat-inactivated fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and 
the samples were incubated at 37˚C in a humidified incubator in an atmosphere of 
5 % CO2/95 % air. The samples were centrifuged (1.5×103, 4˚C, 15 min), and the 
retention percentage was determined using spectrophotometer as described in section 
3.2.5. 
 






3.2.7 Cells  
A549 cells were purchased from ATCC (Manassas, Virginia), maintained in 
DMEM, and supplemented with 10 % heat-inactivated fetal bovine serum, 100 U/ml 
penicillin and 100 g/ml streptomycin. Primary HUVECs were purchased from 
Lonza (Basel, Switzerland), and cultured in endothelial cell basal medium-2 
(Endothelial Basal Medium-2 (EBM-2; Lonza, cat. no. CC-3156). The cells were 
incubated at 37°C in a humidified incubator in an atmosphere of 5 % CO2 / 95 % air. 
 
3.2.8 Cytotoxicity study (WST Assay) 
The cytotoxicity of the CURMS, free curcumin solution, and free 
marinosomes (FM) were evaluated using a Cell Counting Kit-8 (CCK-8; Dojindo, 
Kumamoto, Japan) as previously described after modification (Tagami et al., 2015). 
Briefly, A549 and HUVEC cells were prepared in medium, and seeded into 96-well 
cell incubation plate at a density of 5.0 × 103 cells/well. A549 were pre-incubated for 
48 h and then treated with different concentrations (0, 10, 20, 30, 40 g/ml) of 
CURMS. In addition, the cells were treated with free curcumin, as a positive control, 
that was dissolved in ethanol and diluted by medium to the desired concentrations (0, 
10, 20, 30, 40 g/ml) as previously reported after modification (Tagami et al., 2014), 
where the final ethanol concentration is kept under 0.5 %. Furthermore, the cells were 
treated with FMS prepared with different concentrations of lipids (0, 150, 300, 450, 
600 g/ml) that encapsulate the herein above-mentioned concentrations of curcumin. 
Regarding to HUVEC, the cells were incubated with different concentrations (0, 1.56, 
3.12, 6.25, 12.5 g/ml) of CURMS and free curcumin. The cells were also treated 
with FMS prepared with different concentrations of lipids (0, 23.4, 46.8, 93.8, 188 






g/ml) that encapsulate the specified concentrations of curcumin. After exposure to 
the drug for predetermined time intervals (24, 48, 72 hours) the cells were washed 
with PBS. The PBS was aspirated and then 110 l of the solution mixture (100 l 
medium and 10 l of CCK-8 solution) was added to the wells. After A549 cells were 
incubated for 1 hour and HUVEC cells were incubated for 4 hours, the absorbance 
was measured using microplate reader at 450 nm. The cell viability and cytotoxicity 
were calculated after subtraction of the background absorbance of the medium from 
the total absorbance using the following equations:  
Cell viability %= (Experimental Abs / Control Abs) × 100 
Where Experimental Abs is the absorbance of the wells treated with different 
concentrations of the drug and Control Abs is the absorbance of the wells incubated 
only with medium. The IC50 value, which is the half maximal inhibitory concentration, 
was calculated through linear and nonlinear curve fitting that performed using excel 
function tools. 
 
3.2.9 Statistical Analysis  
All data shown here are represented in “mean value ± S.D.”. The two-way ANOVA, 
with Bonferroni multiple comparison test, was used to assess statistical significance 












3.3. Results and discussion 
3.3.1 CURMs prepared using the thin drug-lipid film hydration 
method 
 Krill lipids extract was reported to be the leading marine phospholipid 
product on the market with approximately 35 % phospholipid (Neptune Technologies 
& Bioressources, 2001). In addition, It was reported that almost half the lipid content 
of Krill presents in a phospholipid form, mainly phosphatidylcholine (Castro-Gómez 
et al., 2015). Phospholipid has a special molecular structure, which contains both 
hydrophilic head group and lipophilic fatty acid group. Subsequently, phospholipids 
have a good emulsifying properties and could be used as natural surfactants to prepare 
emulsion without addition of other emulsifiers (Lu et al., 2012).  Additionally, it was 
reported that the marine extracted lipids have a potential oxidative stability to prepare 
liposomes (Lu et al., 2011). Consequently, in the present study the preparation of 
marinosomes from krill lipid extract and the loading of curcumin at reasonable 
drug-to-lipid ratios are accomplished. CURMs were prepared by incorporating the 
drug into the lipid phase using the thin drug-lipid film method after refluxing the drug 
with the lipids for 2 hours. CURMs have liposome-like vesicle structure because of 
self-assembly property of phospholipids molecules. In reflux, it seems that raising the 
temperature melted the lipids and led to dissolve the curcumin into the lipid phase 
(Maiti et al., 2007). Additionally, curcumin could undergo hydrophobic interaction 
through its aromatic rings and hydrogen bonding through its phenol rings (Began et 
al., 1999). Therefore, the encapsulation efficiency of curcumin into the lipid phase 
increased. As shown in Table 4, the four formulations of CURM and FM prepared by 
extrusion (FME and CURME) in this experiment have uniform sizes. The values of 






the particle size of FME, CURME 10, CURME 15, CURME 20 and CURME 30 are 
118 ± 4, 120 ± 6, 105 ± 8, 101 ± 7 and 120 ± 4, respectively. The zeta potential values 
are ranging from -13 ± 2 mV to -15 ± 1 mV. The particle size distribution of FME and 
CURME has a single peak, as shown in Fig. 21A and B, with a narrow size 
distribution (PDI < 0.12). However, as shown in Table 5, the four formulations of 
CURMs and FMs prepared by sonication method (CURMS and FMS) have uniform 
sizes. The values of the particle size of FMS, CURMS 10, CURMS 15, CURMS 20 
and CURMS 30 are 63 ± 2, 94 ± 4, 81 ± 3, 63 ± 2 and 60 ± 3, respectively. 
Furthermore, The zeta potential values are ranging from -13 ± 1 mV to -15 ± 2 mV. 
The particle size distribution of FMS and CURMS has a single peak, as shown in Fig. 
21C and D, with a slightly wider size distribution (PDI < 0.27) compared to that of 
FME and CURME. In the extrusion method, increasing the lipid/curcumin ratio does 
not show significant effects on particle size, PDI, and zeta potential, as shown in 
Table 4. This is not surprising, as it is well known that the extruded vesicles would be 
close in diameter to the pore size of the polycarbonate membranes used to prepare 
them (MacDonald et al., 1991). Additionally, the difference in the particle size 
between CURME 15 and FME is likely due to the variability of manual pressure 
applied during the extrusion. Particularly, CURME 10 and FME have nearly similar 
particle sizes. However, in sonication method the lipid/curcumin ratio affects the 
particle size of CURMS, as shown in Table 5. As the lipid/curcumin ratio increases 
from 10/1 to 30/1 the particle size decreases from 94 ± 4 to 60 ± 3 nm, respectively, 
in agreement with what is previously reported (Anuchapreeda et al., 2011). In Table 5, 
it is worthy to note that there is a clear difference in particle size between FMS and 
CURMS 15 (63 ± 2 nm and 81 ± 3 nm, respectively). This could be due to the 






incorporation of curcumin in the lipid layer of the liposomes. The negative charge of 
zeta potential values, shown in Table 5, could be due to the partition of the negatively 




Table 4. FM and CURM prepared by extrusion method (FME and CURME)  
CURME prepared by addition of 1 mg curcumin to different weights of lipids 
(10, 15, 20, and 30 mg). FME is free marinosomes prepared with lipid weight = 15 




















Fig. 21. DLS measurements of (A) free marinosomes (FME) prepared 
using extrusion method and (B) curcumin-loaded marinosomes (CURME) 
prepared using extrusion method. The CURME formulations were prepared, at 
lipid/drug ratio of 15/1 w/w, and FME formulations were prepared at lipid 
concentration = 15 mg/ml. The information about PDI and zeta potential are written 





















     Table 5. FM and CURM prepared by sonication method (FMS and 
CURMS) 
CURMS prepared by addition of 1 mg CUR to different weights of lipids (10, 
15, 20, and 30 mg). FMS is free marinosomes prepared with lipid weight = 15 mg/ml. 


























Fig. 21. DLS measurements of (C) free marinosomes (FMS) prepared 
using sonication method and (D) curcumin-loaded marinosomes (CURMS) 
prepared using sonication method. The CURMS formulations were prepared, at 
lipid/drug ratio of 15/1 w/w, and FMS formulations were prepared at lipid 
concentration = 15 mg/ml. The information about PDI and zeta potential are written 
in Table 5. 
 
3.3.2 EE of CURMs 
 The EE measurement of CURMs reveals that the EE increases with the 
increase of lipid concentration up to 15 mg and saturated beyond this level as most of 
the added curcumin amount (1 mg) has been encapsulated, shown in Fig. 22. 
Additionally, the slight decrease in the EE of CURME at high lipid concentration (30 






mg) could be due to the entrapment of a slight amount of lipids between the 
two-polycarbonate membranes during the extrusion method. Particularly, using 
sonication method didn't show that decrease in the EE of the CURMS at the same 
high concentration. In a preliminary experiment, 40 mg amount of lipids was used to 
encapsulate the same amount of curcumin resulted in further decrease in the EE which 
confirm the previous observation. Additionally, the sonication and the extrusion 
methods resulted in almost the same EE. When the CURMs were centrifuged to 
separate the excess curcumin after preparation, pellets of excess curcumin were seen 












Fig. 22. The encapsulation efficiency (EE) of CURMs prepared using 
extrusion (CURME), and sonication (CURMS). Four formulations were prepared 
at lipid/curcumin ratios of 10/1, 15/1, 20/1, and 30/1 (w/w). Data represent the means 
± S.D. (n = 3). No significant differences (p > 0.05) between CURME and CURMS. 






3.3.3 Determination of the antioxidant activity of CURMs in 
detergent buffer 
 In food and biological extracts, the standard DPPH assay is accustomed to be 
used for the in vitro determination of antioxidant activity (Prior et al., 2005). The 
interaction kinetics of DPPH assay with polyphenolic and non-phenolic compounds 
have been recently well studied (Villaño et al., 2007). In case of curcumin, DPPH 
scavenging is accelerated by hydrogen atom transfer or sequential proton loss electron 
transfer mechanism (Feng and Liu, 2009). However, it is well known that the DPPH 
assay uses methanol, ethanol or buffered alcoholic to keep the DPPH soluble for the 
in vitro determination of antioxidant activity. The DPPH scavenging activity of 
CURMs has to be tested in buffer to mimic the in vivo environment, while the DPPH 
is insoluble and unstable in buffer solutions. In the present study, a simple in vitro 
method to measure the antioxidant activity of liposomal formulations in buffer is used 
following a recent report after modification (Nicklisch and Waite, 2014). In a 
preliminary experiment, 0.3 % Triton X-100 was selected to keep 100 M DPPH 
soluble and stable in HBS buffer for up to 40 min, which is the needed time to 
measure the antioxidant activity. The absorbance of DPPH in the HBS-Triton mixture 
is reduced to 80 % after 180 min, shown in section 3.2.3 and Fig. 23. If more time is 
needed, other detergents or buffers have to be tested first. The surfactant molecules 
form micelles at critical micelle concentration, this could help to dissolve and 
stabilize the hydrophobic molecules that are sparingly soluble in aqueous solutions. 
After determination of the antioxidant activity of ascorbic acid as a positive control 
using HBS-Triton mixture, shown in Table 6, we found that EC50 values agree with 
what was reported previously using methanol or buffered methanol solution (Sharma 






and Bhat, 2009). In Fig. 24, increasing the sample concentration resulted in increasing 
the antioxidant activity, which reveals a dose-dependent antioxidant activity. CURME 
and CURMS showed strong DPPH radical scavenging abilities. The antioxidant 
activities (at 25 g/ml) of CURME and CURMS are 91.1 % ± 0.3 % and 89.5 % ± 
2.5 %, respectively, that are as high as that of vitamin C (82.9 % ± 5.8 %) and clearly 
higher than that of curcumin (69.8 % ± 7.6 %). This indicates that CURMs possibly 
react, as electron donors, with free radicals and thus convert them into more stable 
compounds and stop further radical reactions. 
In addition, the EC50 values of CURME and CURMS are 4.0 ± 0.9 g/ml and 4.3 ± 
1.8 g/ml, respectively, which are nearly similar to that of vitamin C (4.5 ± 1.1 
g/ml) and significantly lower than that of curcumin (13.6 ± 2.8 g/ml), shown in 
Table 6.  Furthermore, the curve of the antioxidant activity of CURMs reached 
nearly a stationary phase at a relatively low concentration (12.5 g/ml). Consequently, 
CURMs could be considered as powerful antioxidants with a very high reactivity with 
free radicals. A synergistic antioxidant effect of phospholipid on -tocopherol was 
previously reported (Cho et al., 2001; Moriya et al., 2007). Subsequently, the 
increasing of the CURMs antioxidant activity compared to free curcumin could be 

















Fig. 23. Time course stability of DPPH in methanol, HBS-Triton mixture 



























Fig. 24. The antioxidant activity of CURME, CURMS, free curcumin and FME 
in HBS-Triton mixture using DPPH assay. CURMs were prepared at 
lipid/curcumin ratio of 15/1 (w/w). FM is prepared at lipid concentration = 15 mg/ml. 
CURME, CURMS, free curcumin, and Vitamin C were prepared with different 
concentrations ranging from 1.56 μg/ml to 25 μg/ml. FME were prepared at different 
concentrations of lipids ranging from 23.4 μg/ml to 375 μg/ml, which encapsulate the 
herein above-mentioned curcumin concentrations. Data represent the means ± S.D. (n 
= 6). No significant differences (p > 0.05) between CURMs and vitamin C. (***) 
Significant difference (p < 0.001) and (****) significant differences (p < 0.0001) 
compared to free curcumin. 
 
 













Table 6. EC50 of a maximum scavenging activity of CURMs 
EC50 of CURME, CURMS, free curcumin and FME using DPPH assay, as 















3.3.4 Stability of CURMs under storage condition 
 Physical instability leads to fusion of vesicles or leakage of the encapsulated 
drug. Additionally, curcumin undergoes fast hydrolytic degradation under basic and 
neutral pH conditions, which results in low pharmacological activities (Chen et al., 
2015). Therefore, the storage stability is an important issue for drug delivery 
formulations. In the present study, the physical stability of CURME, CURMS and 
FME including particle size, PDI, and curcumin retention was investigated. 
Additionally, since the antioxidant capacity and free radical scavenging ability could 
be gradually lost during the storage, they have to be measured during and after the 
storage period. CURME, CURMS, and FME (lipid/drug ratio 15/1 w/w) were stored 
at 4˚C for eight weeks. Fig. 25A and 25B reveal that the mean particle diameter and 
PDI of CURME, CURMS and FME did not change significantly during 8 weeks. Fig. 
25C shows that the retention rate of curcumin in CURME and CURMS slightly 
decreased to 89.5 ± 2.5 % and 92.7 ± 1.9 % of their initial values, respectively, after 
storage of 8 weeks. Additionally, no significant change in the antioxidant activity of 
CURME, CURMS, and FME (91.7 ± 0.13, 91.8 ± 0.18 and 26.8 ± 1.4, respectively) 
after storage of 6 weeks at 4˚C as shown in Fig. 25D. However, the oxidative stability 
of CURME and CURMS slightly decreased to 78.7 ± 2.5 % and 79.0 ± 2.7 %, 
respectively, after storage of 8 weeks. This decrease could be due to the decrease in 
the retained curcumin amount (about 10 %, shown in Fig. 25C) after storage of 8 
weeks. Particularly, the oxidative stability of FME shows no significant change after 
storage of 8 weeks. This could imply the utility of marinosomes to incorporate 
hydrophobic drugs and CURMs possess a favorable physical stability when stored at 






4 °C. The physical stability of marine liposomes may be attributed to four different 
factors. The first, the storage at low temperature (4°C) inhibits the membrane fluidity 
of the nanoliposomes  The second, the presence of cholesterol in marine lipids may 
increase the rigidity of marinosomes due to the resistance of cholesterol-incorporated 
liposome toward degradation (Grit et al., 1993). The third, the negative charges of 
phospholipids contribute to electrostatic stability (Lu et al., 2012). The fourth, the 
presence of free fatty acids in the marine lipids and their distribution in the lipid layer 
of marinosomes increase the negative surface charge in agreement with a previous 
report which showed that the the incorporation of alkali fatty acids with phospholipid 
had a positive influence on the surface charge of O/W emulsion (Buszello et al., 
2000). Additionally, the oxidative stability of marine liposomes could be attributed to 
three different factors. The first, the presence of PUFAs in the sn-2 position of the 
phospholipids may forbid oxygen and free radicals to attack PUFAs due to this tightly 
packed molecular conformation (Applegate and Glomset, 1986). The second, the 
presence of other antioxidant compounds like astaxanthin and -tocopherol that are 
potent antioxidants (Castro-Gómez et al., 2015). The third, the presumably synergistic 


































Fig. 25. Stability of CURME, CURMS and FME during storage at 4°C 
for 8 weeks. CURMs were prepared at lipid/curcumin ratio of 15/1 (w/w). FM is 
prepared at lipid concentration = 15 mg/ml. A) Particle size. B) PDI. Data represent 
the means ± S.D. (n = 3). 

























Fig. 25. Stability of CURME, CURMS and FME during storage at 4°C for 8 
weeks. CURMs were prepared at lipid/curcumin ratio of 15/1 (w/w). FM is prepared 
at lipid concentration = 15 mg/ml. C) Curcumin retention %. D) Oxidative stability. 
Data represent the means ± S.D. (n = 3). 
 






3.3.5 Retention of curcumin into marinosomes under cell culture 
condition 
A drug release study was carried out in a medium containing fetal bovine 
serum to mimic in vivo conditions. In the present study, because of the curcumin 
hydrolytic degradation, curcumin retention has been measured instead of drug release 
measurements to study the in vitro drug release. In case of CURMs (lipid/drug ratio of 
15/1 w/w), curcumin retention undergoes initial decrease to reach 80.5 ± 5.5 % 
(CURME) and 88.8 ± 7.9 % (CURMS) of its initial value after 4 hours as shown in 
Fig. 26. Afterward the curcumin retention continued in gradual decrease to 70.1 ± 
5.2 % (CURME) and 75.6 ± 1.1 % (CURMS) during 72 hours. The reason behind the 
high decrease rate of curcumin retention during the early stage of the measurement (~ 
4 hours) is possibly the adsorption of some drug molecules on the surface of CURMs 
during the thin film preparation. It is well known that increasing the content of PUFA 
leads to increasing the fluidity of liposomes under physiological conditions compared 
to that of the saturated lipids (Saiz and Klein, 2001). Krill lipid is a mixture of 
saturated fatty acids, monounsaturated fatty acids, poly-unsaturated fatty acids, 
cholesterol and others as mentioned in section 3.2.1. In addition, nearly half of the 
PUFAs of krill lipid are located in phospholipids (mainly phosphatidyl-choline) as it 
is previously reported (Castro-Gómez et al., 2015; Lu et al., 2011). Consequently, 
increasing the temperature to body temperature leads to increase the fluidity of 
marinosomes due to the presence of PUFAs and thus the curcumin release starts. 
However the presence of saturated fatty acids, phospholipids and cholesterol in krill 
lipid prevents marinosomes from complete fluidity and thus resulted in a controlled 
release phenomenon. The drug release is sustainable (0 - 30 % at 0 - 72 hours), shown 






in Fig. 26, denoting the significance of marinosomes as a drug delivery system. It is 
possible that 30 % of the drug undergoes burst release and controlled release from the 
outer layer of the marinosomes. This result opens the door widely to the in vitro 
anticancer experiment to thoroughly investigate the controlled release of these 













Fig. 26. Retention of curcumin into marinosomes under culture condition. 
CURME and CURMS were prepared at lipid/curcumin ratio of 15/1 (w/w). FM is 
prepared at lipid concentration = 15 mg/ml. CURMs were incubated in medium 










3.3.6 The cytotoxicity of free and curcumin-loaded marinosomes on 
A549 cells: 
A comparative cytotoxicity study to prospect the capability of CURMS to 
deliver highly hydrophobic drugs such as curcumin to lung cancer cells has been 
performed. A549 cells were treated separately with free curcumin as drug solution, 
CURMS and FMS for different times and concentrations. The effect of controlled 
release of curcumin under culture condition (section 3.3.5.) was confirmed when 
cancer cells were used.  
Fig. 27A shows cytotoxicity after incubation with A549 cells for 24 hours, 
free curcumin has a cytotoxic effect of 63.4 ± 6.5 % (the highest) while CURMS 
shows only 10.9 ± 5.9 % at 20 g/ml of curcumin concentration. At incubation time 
equal to 48 hours, free curcumin and CURMS show nearly the same cytotoxic effect 
of 59.3 ± 4.0 % and 55.7 ± 2.5 % at 20 g/ml, respectively, shown in Fig. 27B. 
However, when the incubation time is extended to 72 hours, the cytotoxic effect of 
CURMS increased to 90.9 ± 2.2 % (the highest) and that of free curcumin decreased 
to 45.7 ± 9.2 % at the same curcumin concentration (20 g/ml) as clearly shown in 
Fig. 27C. The IC50 values of free curcumin are 14.3 ± 5.1, 18.2 ± 2.9 and 19.8 ± 2.3 
g/ml at 24, 48 and 72 hours, respectively, stated in Table 7. This means that free 
curcumin gives its ultimate effect on the cell during the early stage of the experiment 
and this may be due to the passive diffusion and accumulation of curcumin directly at 
its action site (Mohanty et al., 2010). While the IC50 values of CURMS are 35.0 ± 1.1, 
19.9 ± 1.03 and 11.7 ± 0.24 g/ml at 24, 48 and 72 hours, respectively. This result 
clearly indicates the sustained release of curcumin from marinosomes over time that 
agrees with previous reports (Ma et al., 2007; Mohanty et al., 2010). It is worthy to 






notice that the cytotoxic effect of FMs is only clear at higher marinosomal doses (450 
and 600 g/ml) in a time- and dose-dependent manner. 
It has been reported that PUFAs are taken up by tumors for use as precursors 
for biochemical metabolic pathways and energy production (Sauer and Dauchy, 1992). 
Once taken up, they are incorporated in the cellular membranes of the tumor and 
contribute to membrane fluidity, ion permeability and elasticity (Merendino et al., 
2013). Plasma membrane is composed of microdomains that include structures known 
as lipid rafts and caveolae, which are rich in cholesterol and sphingolipids, and play a 
key role in cell signal transduction (Ma et al., 2004). The inclusion of n-3 PUFAs in 
tumor cell membranes, especially microdomains, may affect physicochemical 
properties of membranes due to their high unsaturation. This could explain the 
capability of n-3 PUFAs to induce cytotoxic effect in tumor cells through the 
regulation of multiple cellular functions (D’Eliseo and Velotti, 2016). This unique 
property of tumor biochemistry or physiology could be used to target tumors and 
increase the therapeutic effect of a chemotherapy with less side effect (Bradley et al., 
2001; Kuznetsova et al., 2006).  
It was reported that at a relatively high concentration (above 15 g/ml) of 
curcumin-loaded micelles, the cytotoxic effect was reduced due to saturation of the 
endocytic process which resulted in reduced drug entry (Ma et al., 2007; Mohanty et 
al., 2010). However, the current study shows that the cytotoxicity of CURMS at such 
high concentrations increases in a time dependent manner. The cytotoxicity of 
CURMS at 30 and 40 g/ml is 96.6 ± 0.2 %, and 96.6 ± 0.2 % after 72 hours. This 
could be due to the affinity of PUFAs to microdomains that may lead to incorporation 
of the marinosomes into the plasma membrane and enhance the internalization of 






curcumin. Additionally, A549 cells were reported to employ multiple endocytotic 
pathways (Kuhn et al., 2014) that possibly localize CURMs in intracellular vesicles. 
Afterword, a gradual release of curcumin from CURMs occurred resulted in a 
























Fig. 27. In vitro cytotoxic effect of CURMS and FMS on A549 lung cancer cells.   
The cells were treated with CURMS, free curcumin, and FMS. CURMS were 
prepared by sonication at lipid/curcumin ratio of 15/1 (w/w). FMS is prepared at lipid 
concentration = 15 mg/ml. (A) After incubation for 24 hours, (B) After incubation for 
48 hours and (C) After incubation for 72 hours. Data represent the means ± S.D. (n = 
3). There is (*) Significant difference (p < 0.05), (**) significant differences (p < 













Table 7. IC50 values of CURMS, free curcumin and FMS against A549 lung 
cancer cells and HUVEC cell line. 
Both cell lines were assayed for cell viability by WST-assay at 24 hours, 48 
hours and 72 hours as shown in Fig. 27 and Fig 28. The IC50 values were calculated 
using excel function tools. NA is the non-available IC50 values of FMS as their 
concentrations were not enough to reach 50 % cytotoxic effect in the present study. 











3.4.7 The effect of free and curcumin-loaded marinosomes on 
HUVECs  
The formation of new blood vessels is a natural process called angiogenesis 
and it is essential during wound healing and embryonic development (Madri et al., 
1991). However, many pathologies, including tumor growth, are arising from 
uncontrolled angiogenesis (Carmeliet et al., 2003). Endothelial cells are among the 
essential cells that constitute the dynamic environment of tumors as they form the 
blood vessels. It was reported that curcumin is able to inhibit the proliferation of 
HUVECs and act as anti-angiogenic compound (Thaloor et al., 1998). In addition, it 
was reported that n-3 PUFAs have anti-angiogenic effect (Szymczak et al., 2008). 
Consequently, the time- and dose-response of CURMS, FMS and free curcumin on 
HUVEC growth were investigated in the present study. CURMS inhibited the 
proliferation of HUVECs in a dose-dependent manner as shown in Fig. 28. The 
highest cytotoxic effect of CURMS and free curcumin were observed at 6.25 g/ml 
after 24 hours (85.2 ± 1.1 % and 50.2 ± 4.5 %, respectively), shown in Fig. 28A. 
Additionally, The IC50 values of CURMS and free curcumin at 24 hours are (2.64 ± 
0.21, 5.73 ± 2.1 μg/ml, respectively, shown in Table 7. The highest cytotoxic effect 
of FMS is (44.7 ± 8.7 %) at concentration of 188 μg/ml after 48 hours, and this could 
be due to the low concentrations of lipids that were used in this experiment. 
The trends of the cytotoxic effects of CURMS, shown in Fig. 28, don't 
indicate obvious change in the cell viability after incubation for more than 24 hours 
(Fig. 28B and C), and thus no controlled release has been observed in this case. It 
was reported that the cellular membrane of endothelial cells is high in caveolae 
(Cohen et al., 2004) and that HUVEC cells express more caveolins than others (Voigt 






et al., 2014). This observation is previously used to target HUVEC cells using 
negatively charged lipid nanoparticles, without the need for cell-specific targeting 
ligands, depending on the high affinity of the lipophilic nanoparticles for caveolae 
(Voigt et al., 2014). This could lead to a high incorporation of CURMS into caveolae 
and a fast release of curcumin inside the HUVEC cells, and thus the ultimate 
cytotoxic effect occurred directly after incubation for 24 hours. However, further 
experiments to determine the uptake pathways of A549 and HUVEC cells for 

























Fig. 28. In vitro cytotoxic effect of marinosomes on HUVEC cell line. The 
cells were treated with CURMS, free curcumin, and FMS. CURMS were prepared by 
sonication at lipid/curcumin ratio of 15/1 (w/w). FM is prepared at lipid concentration 
= 15 mg/ml. (A) After incubation for 24 hours, (B) After incubation for 48 hours and 
(C) After incubation for 72 hours. Data represent the means ± S.D. (n = 3). There is 
(**) significant differences (p < 0.01), (***) significant differences (p < 0.001) and 
(****) significant differences (p < 0.0001) between CURMS and free curcumin. 
 








The present study exhibits the encapsulation of curcumin into krill 
lipid-based liposomes through utilizing a modified thin drug-lipid film hydration 
method followed by extrusion or sonication. CURMs of uniform diameter, and 
narrow PDI were prepared with high encapsulation efficiency (92.0 ± 5.9 %) at a 
lipid/drug ratio of 15/1 (w/w). This approach resulted liposomal formulations of high 
physicochemical and oxidative stability. The krill lipids-based curcumin-loaded 
liposomes prepared in this study exhibited an effective cytotoxic effect after 72 hours 
on A549 cells due to the controlled release phenomenon and after 24 hours on 
HUVEC cells. These nano-nutraceutical liposomal formulations represent low-cost 
drug delivery systems that could be applied for efficient solubilization, stabilization 
and controlled delivery of the biological active and hydrophobic compounds for 
cancer and other inflammatory diseases targeting. However, exact mechanism by 
which CURMs exert antioxidant and anticancer effect is not elucidated in the present 
work. Furthermore, other functionalities of marinosomes relevant to 
biopharmaceutical field like controlled release, solubilizing other hydrophobic drugs, 
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